Edition:
United States

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

3.00USD
17 Aug 2018
Change (% chg)

$0.10 (+3.45%)
Prev Close
$2.90
Open
$2.88
Day's High
$3.05
Day's Low
$2.88
Volume
8,631
Avg. Vol
55,674
52-wk High
$4.55
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Aptose Reports Q1 Loss Per Share $0.23
Thursday, 10 May 2018 04:00pm EDT 

May 10 (Reuters) - Aptose Biosciences Inc ::APTOSE REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018.Q1 LOSS PER SHARE $0.23.  Full Article

Aptose Biosciences Establishes New At-The-Market Facility
Wednesday, 28 Mar 2018 08:00am EDT 

March 28 (Reuters) - Aptose Biosciences Inc ::APTOSE BIOSCIENCES ESTABLISHES NEW AT-THE-MARKET FACILITY.APTOSE BIOSCIENCES INC SAYS ENTERED INTO AN "AT-THE-MARKET" SALES AGREEMENT WITH CANTOR FITZGERALD & CO.APTOSE BIOSCIENCES - AS PER SALES AGREEMENT, CO MAY, FROM TIME TO TIME, ISSUE & SELL THROUGH CANTOR, ACTING AS SOLE AGENT, COMMON SHARES OF CO.APTOSE BIOSCIENCES INC - NEW AT-THE-MARKET FACILITY REPLACES PREVIOUS ATM THAT EXPIRED IN DECEMBER 2017.  Full Article

Aptose Reports Qtrly Loss Of $0.12‍​ Per Share
Tuesday, 27 Mar 2018 04:15pm EDT 

March 27 (Reuters) - Aptose Biosciences Inc ::APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017.APTOSE BIOSCIENCES INC - QTRLY LOSS PER SHARE $0.12‍​.APTOSE BIOSCIENCES - ‍TOTAL CASH AND CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017 WERE $11.4 MILLION​.APTOSE BIOSCIENCES - ‍BASED ON CURRENT ESTIMATIONS, CO HAS SUFFICIENT RESOURCES TO FUND RESEARCH, DEVELOPMENT AND OPERATIONS INTO Q1 2019​.  Full Article

Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln
Wednesday, 7 Feb 2018 03:26pm EST 

Feb 7 (Reuters) - Aptose Biosciences Inc ::APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia
Tuesday, 26 Dec 2017 07:30am EST 

Dec 26 (Reuters) - Aptose Biosciences Inc ::FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA.  Full Article

Aptose Biosciences Files For Offering Of Up To 6 Mln Of Its Common Shares By The Selling Shareholder
Tuesday, 28 Nov 2017 04:29pm EST 

Nov 28 (Reuters) - Aptose Biosciences Inc ::APTOSE BIOSCIENCES INC FILES FOR OFFERING OF UP TO 6.0 MILLION OF CO'S COMMON SHARES BY THE SELLING SHAREHOLDER - SEC FILING‍​.  Full Article

Aptose Biosciences Inc Q3 loss per share C$0.14
Tuesday, 14 Nov 2017 04:00pm EST 

Nov 14 (Reuters) - Aptose Biosciences Inc :Aptose reports results for the third quarter ended September 30, 2017.Q3 loss per share C$0.14.Aptose Biosciences Inc - ‍total cash and cash equivalents and investments as of September 30, 2017 were $13.6 million​.  Full Article

Aptose Biosciences Inc qtrly earnings per share $0.15
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Aptose Biosciences Inc :Aptose reports results for the second quarter ended June 30, 2017.Aptose Biosciences Inc qtrly earnings per share $0.15.  Full Article

Aptose Q1 loss per share C$0.25
Thursday, 11 May 2017 04:02pm EDT 

May 11 (Reuters) - Aptose Biosciences Inc ::Aptose reports results for the first quarter ended March 31, 2017.Q1 loss per share C$0.25.  Full Article

Aptose reports Q4 and year end 2016 results
Tuesday, 28 Mar 2017 05:03pm EDT 

Aptose Biosciences Inc - : Aptose reports fourth quarter and year end 2016 results .Q4 loss per share c$0.26.  Full Article

BRIEF-Aptose Reports Q1 Loss Per Share $0.23

* APTOSE REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2018